Interestingly, Zhou et al. found that in ccRCC tissues, HHLA2 expression was more prominent than PD-L1 both in the training and validation cohorts—the authors found 44.2% (91/206) and 41.1% (81/197) HHLA2-positive samples and 33.0% (68/206) and 32.0% (63/197) PD-L1-positive samples, respectively [12]. This evidence concerns the gene HHLA2 and nonpapillary renal cell carcinoma.